Post-radiotherapy Rhinosinusitis in Children

Study Overview
=================
Brief Summary
-----------------
Chronic rhinosinusitis (CRS) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. However, while radiological involvement is frequent, clinical expression seems less important. Few studies have investigated the incidence of this condition in the pediatric population while its evolution seems to be very chronic even if a partial improvement may occur with time. Our objective is therefore to study the impact of CSR in children treated for cancer of the cervicofacial region, to evaluate its incidence and medium-term evolution in order to determine whether it is necessary to set up a specific follow-up in these patients. The clinical impact of CSR is assessed by a specific SNOT 22 questionnaire in children treated for a head-neck mesenchymal malignancy in comparison with a control population consisting of children treated for a mesenchymal malignancy of non-head-neck location.

Official Title
-----------------
Evaluation of Chronic Rhinosinusitis in Children Managed for Cervicofacial Mesenchymal Malignancy

Conditions
-----------------
Pediatric Cancer, Chronic Sinusitis

Intervention / Treatment
-----------------
* Other: SNOT 22 questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study population: all patients under 18 years of age managed for a head neck mesenchymal cancer between January 1, 2018 and December 31, 2024 Control population: all patient under 1 years of age managed for non -head neck mesenchymal cancer between January 1, 2018 and December 31, 2024 Exclusion Criteria: Patients with hematological tumors; Patients with mucociliary pathologies or proven allergic rhinitis before the diagnosis of cancer Patients who have required surgical treatment that has removed more than half of the sinus cavities Tumor recurrence at the time of inclusion Sinus surgery between the last radiological check-up and inclusion Administrative reasons: inability to receive informed information.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Exposed patients<br> | Other: SNOT 22 questionnaire<br>* 22 items, score between 0 and 5; sum, minimum = 0, maximum = 110; higher score = higher impact on quality of life)<br>|
| Non exposed patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of CRS in pediatric patients by Sino-Nasal Outcome Test-22 (SNOT 22) |  | >1 year to <4 years after the end of oncologic treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of CRS in pediatric patients after head neck mesenchymal cancer management |  | 1 year after the end of the oncologic treatment | 
| Correlation between SNOT 22 and clinical assessment by PADORES score |  | >1 year to <4 years after the end of oncologic treatment | 
| Correlation between SNOT 22 and clinical assessment by lund-kennedy score |  | >1 year to <4 years after the end of oncologic treatment | 
| Correlation between SNOT 22 and radiological assessment by Lund-Mackay score |  | >1 year to <4 years after the end of oncologic treatment | 
| Radiological evolution of CRS by Lund-Mackay score |  | >1 year to <4 years after the end of oncologic treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality of life, Post-treatment chronic sinusitis, Pediatric cancer, Sinusitis